Q&A on the Recent Spike of Respiratory Viruses

by EpicentRx | Nov 3, 2022 | Blog

Just when we thought it was safe to go back in the water, and as if we didn’t have enough scary words to contend with, a new one making the rounds is “tripledemic”, involving simultaneous infection with COVID, the flu, and RSV. Yikes…more viral spikes! The proverb...

Dr. Tony Reid, MD, PhD interview with Oncology Tube – REPLATINUM Phase III

by EpicentRx | Nov 2, 2022 | Media

The Dictatorship of Cancer: How to Topple it in Three – Not So Easy – Steps

by EpicentRx | Oct 26, 2022 | Media

What do dictators and the military have in common with tumors and stroma? The answer: symbiosis – a relationship in which two different types closely and intimately interact with each other to the benefit of at least one of the types. The famous phrase, “no man is an...

EpicentRx Announces First Patient Dosed in China for the Phase 3 REPLATINUM Global Study with RRx-001 in Third Line and Beyond Extensive Stage Small Cell Lung Cancer (SCLC)

by EpicentRx | Oct 6, 2022 | 2022, Press Releases

License partner SciClone Pharmaceuticals oversees trial in China. Phase 3 REPLATINUM multicenter clinical trial with over 50 sites in the U.S. and China is underway Torrey Pines, Calif., Oct. 6, 2022 /PRNewswire/ – EpicentRx, a late clinical stage...

AdAPT-001 Does It Beta

by EpicentRx | Oct 4, 2022 | Blog

What do U.S. fraternities and sororities, the Bible, COVID-19 (e.g., the alpha, delta, omicron variants) and EpicentRx’s AdAPT-001 oncolytic adenovirus have in common? Answer: Ancient Greek letters. EpicentRx’s AdAPT-001 oncolytic adenovirus carries a “TGF-beta trap.”...